Research programme: cancer therapy - STIL BioTechnologiesAlternative Names: SB 144; SSP 1; SSP 5; YM 17; YM 27
Latest Information Update: 26 Jan 2007
At a glance
- Originator STIL BioTechnologies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 16 Jul 2003 Preclinical trials in Non-small cell lung cancer in Israel (unspecified route)